Bridging the Gap: Conference Workbook [International Conference on AIDS (12th: 1994: Geneva, Switzerland)]

Monday, June 29

OSTR S

12377 Risk factors for diabetes mellitus in HIV-positive patients
Stefan Mauss*; E. Wolf; R. Pascucci; G. Virg; E. Jaegel-Guedes;
H. Jaeger, Germany
12378 Drug monitoring of saquinavir during monotherapy or in combination
with ritonavir in patients with chronic liver disease
Peter Langmann*; H. Klinker; A. Schubert; C. Writh; E. Richter, Germany
12379 Sterile leucocyturia and reversible impairment of renal function in
indinavirtreated patients
Volker Rickerts*; H. Hanel; T. Leder; S. Stazzewski; W. Stille, Germany
12380 A pharmacokinetic interaction evaluation of MKC-442 and nelfinavir
(NFV) in healthy male and female volunteers
M. Robert Blum*; C.P. Moxham; DJ. Kargl; J.B. Quinn; D. W. Barry;
F.S. Rousseau, USA
12381 The effects ofantiretroviral protease inhibitors (PIs) on serum lipids and
glucose in HIV-infected patients
Edmond Chang* M. Deleo; Y.T. Liu; D. Tetreault; G. Beall, USA
12382 In vitro inhibition of cytochromes P-450 2D6 and 3A4 by HIV protease
inhibitors
Anne-Florence Rasca*; P. Bonnabry; P. Dayer, Switzerland
12383 The treatment (Tx) of nelfinavir (NFV)-induced diarrhea (NFVID)
Kristen Razzeca*; Sandra Odenheimer; Margaret Davis;
Karen Landeck, USA
12384 Atovaquone suspension and indinavir have minimal pharmacokinetic
interactions
Alain Emmanuel*; Catherine Gillotin; R. Farinotti;
B.M. Sadler, France
12385 HIV Adverse Drug Reaction (ADR) Reporting Scheme
Malcolm Hooker*; P.R. Arlett; G.H. Lee; A.H. Cave; J.H. Darbyshire;
A.M. Breckenridge; M. Rawlins, UK
12386 Safety of adefovirdipivoxil in the treatment of HIV-infection
Steven Barriere*; D. Winslow; D. Coakley;J. Rooney, USA
12387 Hyperglicemia associated with protease inhibotor therapy
Montserrat Sala Rodo*; R. Pena C.; M. Cervantes; B. Font; G. Serrate;
F. Segura, Spain
12388 The loin pain/indinavir syndrome and urolithiasis associated with
indinavir therapy
Mark R. Nelson*; Brian Gazzard; R.S. Kooner; G. Smith; K. Jordan;
M. Dineen; J. Ramsay, UK
12389 Pharmacokinetic drug interactions with amprenavir
Brian Sadler*; C. Gillotin; G.E. Chittick; W. TSymonds, USA
12390 Prediction of in vivo impairment of cytochrome P450-mediated
metabolism by HIV protease inhibitors
Pascal Bonnabry*; A.F. Rasca; T. Leemann; P. Dayer, Switzerland
12391 indinavir-associated facial atrophy in HIV-positive patients
Ka Hing Wong*; Tin Yee Ho; C. W. Chan; K.H. Wong;S.S. Lee,
Hong Kong (China)
12392 The incidence and severity of diarrhea in HIV+ patients from a large,
Urban Medical Center who have taken nelfinavir in the past twelve
months

Janet M. Kosmyna*; Janet M. Kosmyna; R.D. MacArthur, USA

12393 Safety profile of Viracept in the treatment of HIV patients: The French
compassionate use program experience
Christine D.E.L.M.A.S.*; D. Szafir; A. Trylesinski; M. Andriamanamihaja;
P. Correia; E. Dohin;J.M. Goers, France
12394 Evaluation of urinary pH and specific gravity in the development of
indinavir induced renal stones
John Gerber*; S. Johnson, USA
12395 Evaluation of protease inhibitor-associated hyperglycemia
in a university-based HIV clinic
Richard Caldwell*; A. Rothstein; C. Allmon; J.G. Montoya; A. Zolopa, USA
12396 Managing the indinavir/Nevirapine interaction via U.S. prescriber
education on dosing strategies
Sarah Lewis*; Lidia Gajewski; A. HoKean; G. Y. Vanscoy, USA
12397 Peripheral neuropathy during stavudine-didanosine combination
therapy (QUINTETTrial)
Francois Raffi*; Jean Marie Mussini; V. Reliquet; J.M. Chennebault;
A. La Feuillade; F. Raffi, France
12398 Expanding the spectrum of protease inhibitors-induced lipodistrophy
Vicente Boix*; S. Reus; M. Priego; E. Merino; F. Roman; E. Climent;
J. Portilla, Spain
12399 Indinavir-related nephrolithiasis is associated with environmental
temperature
E. Martinez*; M. Leguizamon; A. del Rio; A. Rodriguez; J.M. Gatell, Spain
12400 Factors related to adherence (ADH) with protease inhibitors
Patrick M. Nemechek*; Maura Conry; Alex Westerfelt; Byron Eicher;
George Wine Chase, USA
12401 Nelfinavir-associated diarrhea is manageable with nonprescription
medications
Trevor Hawkins, USA
12402 Patterns of nausea with combination antiretroviral therapy induction
Nancy Reynolds*;J. Neidig; R. Vocca, USA
12403 Buffalo Hump associated with proteasa inhibitors and use of corticoids
ointment
Pompeyo Viciana*; M. Dolores Prados; P. Viciana; G. Gomez Vera;
E. Cordero; J.L. Villanueva; J. Caballero; J. Pachon, Spain
NOTES

CONFERENCE WORKBOOK

37